Navigation Links
Aratana Therapeutics Appoints Erick Lucera Vice President of Corporate Development
Date:1/24/2013

KANSAS CITY, Kan. and NEW YORK, Jan. 24, 2013 /PRNewswire/ -- Aratana Therapeutics, a biopharmaceutical company developing innovative medicines for cats and dogs (companion animals), today announced the appointment of Erick Lucera as Vice President of Corporate Development.  Mr. Lucera will leverage his broad experience managing investments in healthcare, as well as his network of industry contacts to facilitate business development and investment initiatives for Aratana.

Steven St. Peter , M.D., President and Chief Executive Officer of Aratana Therapeutics, stated, "Erick is well known in the healthcare industry and we are very excited to add him to our team.  His deep understanding of corporate strategy and proven ability to recognize and invest strategically in strong growth opportunities will be paramount to keeping Aratana on its current trajectory."

Mr. Lucera stated, "Aratana represents one of the most attractive investment models I've seen in my 15 years as a healthcare investor.  I am confident the human health industry is beginning to recognize the strategic importance and remarkable value in developing animal health strategies for their assets.  As part of my commitment to positioning Aratana as the partner of choice for these companies, I look forward to bringing in high-quality assets and delivering significant value through successful execution on our business initiatives."

Erick Lucera
Mr. Lucera has more than 15 years of diverse experience in the healthcare public equity markets.  Prior to joining Aratana, Mr. Lucera spent four years as Vice President and Healthcare Analyst at Eaton Vance Investment Managers.  From 2004 to 2007, Mr. Lucera was a Portfolio Manager at Intrepid Capital, where he successfully constructed and managed a portfolio constructed across biotech, pharmaceutical, device, and service companies.  Prior to that, Mr. Lucera held various leadership positions at Independence Investments, including Head of Healthcare Research.  Mr. Lucera began his career as a staff auditor and accountant at PwC.  He holds a CPH in public health from Harvard University, and M.S.F. in quantitative finance from The Wallace E. Carroll Graduate School of Management of Boston College, an MBA from Indiana University Bloomington and a B.S. in accounting from Lerner College of Business and Economics of University of Delaware.

About Aratana Therapeutics
Aratana Therapeutics is a biopharmaceutical company positioned to deliver high quality new medicines that address significant therapeutic needs for cats and dogs (companion animals).  Aratana licenses and develops proprietary, patent-protected compounds acquired from human pharmaceutical and biotechnology companies and then develops strategies to maximize the value of the programs for the animal health market.  For more information, please visit www.aratanatherapeutics.com.

For Investors & Media:
Joshua Drumm , Ph.D. / Andrew Mielach
Tiberend Strategic Advisors, Inc.
(212) 827-0020  
jdrumm@tiberend.com   
amielach@tiberend.com


'/>"/>
SOURCE Aratana Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Aratana to Present at Bank of America Merrill Lynch Animal Health Summit
2. Aratana to Participate in Leerink Swanns November Management Access Days
3. Epigenetics Technology Market (Epigenomics, DNA Methylation, Histone Modifications, RNA Interference, Cancer Therapeutics, Personalized Medicine) (2012 - 2017)
4. Topokine Therapeutics Secures Financing from Schooner Capital to Advance Clinical Development of XAF5 Gel
5. PrimeMail, Prime Therapeutics mail-service pharmacy, receives URAC Reaccreditation
6. Northwest Biotherapeutics, Inc. Announces Full Exercise of Over- Allotment Option
7. Cadence Pharmaceuticals Announces Termination of Option Agreement to Acquire Incline Therapeutics, Inc.
8. Isis Pharmaceuticals And AstraZeneca Form Strategic Alliance On RNA Therapeutics For Cancer
9. Fred Hutchinson Cancer Research Center Partners With GlaxoSmithKline to Develop Muscular Dystrophy Therapeutics
10. Northwest Biotherapeutics Announces Public Offering of Common Stock and Warrants, and Listing on NASDAQ
11. PTC Therapeutics Announces European Medicines Agency Validation of Marketing Authorization Application for Ataluren in Duchenne Muscular Dystrophy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/10/2017)... -- Physical Rehabilitation Network (PRN), acquired the long-standing outpatient rehabilitation clinic, ... . The reputable clinic will continue to be co-owned and ... staff of four clinicians. Lipkin received his doctorate in physical ... years of experience with a strong background in manual therapy. ... 10th PRN clinic in and around the Denver ...
(Date:8/7/2017)... 7, 2017 Insightin Health, provider of ... and engagement, announced the selection of Michael ... Development, effective as of February 2017. In this role, ... strategy for our clients. Wood brings with him ... and business analytics within the healthcare industry. Wood ...
(Date:8/7/2017)... Pharmacy, Inc. (NYSE: DPLO), the nation,s largest independent specialty pharmacy, ...  All comparisons, unless otherwise noted, are to the quarter ended ... Second Quarter 2017 Highlights include: Revenue ... 3.5% Total prescriptions dispensed of 220,000, compared ... 7.6% Gross profit per prescription dispensed ...
Breaking Medicine Technology:
(Date:8/18/2017)... ... 2017 , ... “Three Narrow Roads”: a vivid and provocative look into the ... Dr. Burnett King Sr., is currently the pastor-teacher-visionary at Simply the WORD Church, a ... Inc., a track-and-field program geared towards youth. , King shares, “When I take time ...
(Date:8/18/2017)... ... August 18, 2017 , ... Rollon Skin Care ... skincare solutions, recently announced the launch of two new skincare products, Prache ... effective alternative to expensive plastic surgery or in-patient cosmetic dermatological procedures. , “We ...
(Date:8/18/2017)... ... ... the Snake”: an entertaining and moral-based short story about an unkind snake learning a ... Jr., a husband, father and grandfather who served as a U.S. Marine, U.S. Army ... for children and teens. My goal is to teach kids to use good judgement ...
(Date:8/17/2017)... Mass (PRWEB) , ... August 17, 2017 , ... ... use by health care organizations and considered extremely effective, very effective, or effective ... Physicians and Physician Leadership”. , NEJM Catalyst Insights Reports are based on surveys ...
(Date:8/17/2017)... ... August 17, 2017 , ... Industry CEOs, life ... for Anti-Infectives Rx. This off-the-record networking forum of the Boston Biotech Conference series ... School. , Industry leaders and decision makers will discuss issues facing the development ...
Breaking Medicine News(10 mins):